Human polyclonal antibodies produced through DNA vaccination of transchromosomal cattle provide mice with post-exposure protection against lethal zaire and Sudan ebolaviruses

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Bounds, Callie E ^a   Kwilas, Steven A ^a   Kuehne, Ana I ^a   Brannan, Jennifer M ^a   Bakken, Russell R ^a   Dye, John M ^a   Hooper, Jay W ^a   Dupuy, Lesley C ^a   Ellefsen, Barry ^c   Hannaman, Drew ^c   Wu, Hua ^b   Jiao, Jin An ^b   Sullivan, Eddie J ^b   Schmaljohn, Connie S ^a   Schnell, Matthias Johannes ^d  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SAB Biotherapeutics   (United States)

^c Ichor Medical Systems Inc   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; ALPHA BETA INTERFERON RECEPTOR; EBOLA VACCINE; IFNAR1 PROTEIN, MOUSE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; BOVINE; CHROMOSOME; CONTROLLED STUDY; DNA IMMUNIZATION; EBOLAVIRUS; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; POST EXPOSURE PROPHYLAXIS; SUDAN EBOLAVIRUS; SURVIVAL; VESICULOVIRUS; VIRUS NEUTRALIZATION; ZAIRE EBOLAVIRUS; ANIMAL; BAGG ALBINO MOUSE; DEMOCRATIC REPUBLIC CONGO; GENETICS; HEMORRHAGIC FEVER, EBOLA; HUMAN; HUMAN ARTIFICIAL CHROMOSOME; IMMUNOLOGY; METABOLISM; PROCEDURES; SUDAN; TRANSGENIC ANIMAL; VACCINATION; VIROLOGY;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CATTLE; CHROMOSOMES, ARTIFICIAL, HUMAN; DEMOCRATIC REPUBLIC OF THE CONGO; EBOLA VACCINES; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; POST-EXPOSURE PROPHYLAXIS; RECEPTOR, INTERFERON ALPHA-BETA; SUDAN; VACCINATION; VACCINES, DNA;

EID: 84947807034     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137786     Document Type: Article

References (44)

1. Feldmann H, Jones S, Klenk HD, Schnittler HJ Ebola virus: from discovery to vaccine. Nature reviews Immunology. 2003; 3(8):677-85. PMID: 12974482
2. Feldmann H, Klenk HD Filoviruses. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston (TX) 1996.
3. Feldmann H, Slenczka W, Klenk HD. Emerging and reemerging of filoviruses. Archives of virology Supplementum. 1996; 11:77-100. PMID: 8800808
4. Kuhn JH. Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. Archives of virology Supplementum. 2008; 20:13-360. PMID: 18637412
5. Emond RT, Evans B, Bowen E.T., Lloyd G. A case of Ebola virus infection. British medical journal. 1977; 2(6086):541-4.
6. Mupapa K, Massamba M, Kibadi K., Kuvula K, Bwaka A, Kipasa M., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. The Journal of infectious diseases. 1999; 179 Suppl 1:S18-23. PMID: 9988160
7. Parren PW, Geisbert TW, Maruyama T, Jahrling P.B., Burton DR. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. Journal of virology. 2002; 76(12):6408-12. PMID: 12021376
8. Oswald WB, Geisbert TW, Davis K.J., Geisbert JB, Sullivan NJ, Jahrling PB, et al Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS pathogens. 2007; 3(1): e9. PMID: 17238286
9. Dye JM, Herbert AS, Kuehne A.I., Barth JF, Muhammad MA, Zak SE, et al Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(13):5034-9. doi: 10.1073/pnas.1200409109 PMID: 22411795
10. Marzi A, Yoshida R, Miyamoto H., Ishijima M, Suzuki Y., Higuchi M, et al. Protective efficacy of neutralizing monoclonal antibodies inanonhuman primate model of Ebola hemorrhagic fever. PloSone. 2012; 7(4): e36192. doi: 10.1371/journal.pone.0036192 PMID: 22558378
11. OlingerGG Jr, Pettitt J, Kim D., Working C, Bohorov O, Bratcher B., et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(44):18030-5. doi: 10.1073/pnas.1213709109 PMID: 23071322
12. Qiu X, Audet J, Wong G., Pillet S, Bello A, Cabral T., et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Science translational medicine. 2012; 4 (138): 138ra81. doi: 10.1126/scitranslmed.3003876 PMID: 22700957
13. Qiu X, Wong G, Audet J., Bello A, Fernando L, Alimonti J.B., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520):47-53. doi: 10.1038/nature13777 PMID: 25171469
14. Choi WY, Hong KJ, Hong J.E., Lee WJ. Progress of vaccine and drug development for Ebola preparedness. Clinical and experimental vaccine research. 2015; 4(1):11-6. doi: 10.7774/cevr.2015.4.1.11 PMID: 25648233
15. Sano A, Matsushita H, Wu H., Jiao JA, Kasinathan P, Sullivan EJ, et al Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattle. PloSone. 2013; 8(10): e78119. doi: 10.1371/journal.pone.0078119 PMID: 24205120
16. Kuroiwa Y, Matsushita H, Sano A. Complex chromosome engineering for production of human antibodies in transgenic animals. Google Patents; 2014.
17. Matsushita H, Sano A, Wu H., Jiao JA, Kasinathan P, Sullivan EJ, et al Triple immunoglobulin gene knockout transchromosomic cattle: bovine lambda cluster deletion and its effect on fully human polyclonal antibody production. PloSone. 2014; 9(3): e90383. doi: 10.1371/journal.pone.0090383 PMID: 24603704
18. Hooper JW, Brocato RL, Kwilas S.A., Hammerbeck CD, Josleyn MD, Royals M, et al DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Science translational medicine. 2014; 6(264): 264ra162. doi: 10.1126/scitranslmed. 3010082 PMID: 25429055
19. Kwilas S, Kishimori JM, Josleyn M, Jerke K., Ballantyne J, Royals M, et al A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates. Current gene therapy. 2014; 14(3):200-10. PMID: 24867065
20. Martins K, Carra JH, Cooper CL, Kwilas S.A., Robinson CG, Shurtleff AC, et al. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein. Viral immunology. 2015; 28 (1):62-70. doi: 10.1089/vim.2014.0071 PMID: 25514232
21. Grant-Klein R.J., Altamura LA, Badger CV, Bounds C.E., Van Deusen NM, Kwilas SA, et al. Codon-Optimized Filovirus DNA Vaccines Delivered by Intramuscular Electroporation Protect Cynomolgus Macaques from Lethal Ebola and Marburg Virus Challenges. Human vaccines & immunotherapeutics. 2015; 11(8): in press.
22. Dias JM, Kuehne AI, Abelson D.M., Bale S., Wong AC, Halfmann P, et al. A shared structural solution for neutralizing ebolaviruses. Nature structural & molecular biology. 2011; 18(12):1424-7.
23. Regules JA, Beigel JH, Paolino K.M., Voell J., Castellano AR, Munoz P, et al A Recombinant Vesicular Stomatitis Virus Ebola Vaccine - Preliminary Report. The New England journal of medicine. 2015.
24. Bray M, Davis K, Geisbert T., Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. The Journal of infectious diseases. 1998; 178(3):651-61. PMID: 9728532
25. Calain P, Monroe MC, Nichol ST Ebola virus defective interfering particles and persistent infection. Virology. 1999; 262(1):114-28. PMID: 10489346
26. Chen G, Koellhoffer JF, Zak S.E., Frei JC, Liu N, Long H, et al Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. ACS chemical biology. 2014; 9 (10):2263-73. doi: 10.1021/cb5006454 PMID: 25140871
27. Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. The Journal of general virology. 2001; 82(Pt 6):1365-73.
28. Lever MS, Piercy TJ, Steward J.A., Eastaugh L., Smither SJ, Taylor C, et al. Lethality and pathogenesis of airborne infection with filoviruses in A129 alpha/beta -/- interferon receptor-deficient mice. Journal of medical microbiology. 2012; 61(Pt 1):8-15. doi: 10.1099/jmm.0.036210-0 PMID: 21852521
29. Grant-Klein R.J., Van Deusen NM, Badger CV, Hannaman D, Dupuy L.C., Schmaljohn CS. Amultiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Human vaccines & immunotherapeutics. 2012; 8(11):1703-6.
30. Khawaja G, Buronfosse T, Jamard C, Abdul F., Guerret S, Zoulim F, et al In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins. Virology. 2012; 433 (1):192-202. doi: 10.1016/j.virol.2012.07.014 PMID: 22921316
31. Ogunremi O, Pasick J, Kobinger GP, Hannaman D, Berhane Y, Clavijo A., et al. A single electroporation delivery of a DNA vaccine containing the hemagglutinin gene of Asian H5N1 avian influenza virus generated a protective antibody response in chickens against a North American virus strain. Clinical and vaccine immunology: CVI. 2013; 20(4):491-500. doi: 10.1128/CVI.00577-12 PMID: 23365205
32. van Drunen Littel-van den Hurk S, Lawman Z, Snider M, Wilson D, van den Hurk JV, Ellefsen B, et al. Two doses of bovine viral diarrhea virus DNA vaccine delivered by electroporation induce long-term protective immune responses. Clinical and vaccine immunology: CVI. 2013; 20(2):166-73. doi: 10.1128/CVI.00565-12 PMID: 23220999
33. Zeitlin L, Pettitt J, Scully C., Bohorova N, Kim D., Pauly M, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebolavirus immunoprotectant. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(51):20690-4. doi: 10.1073/pnas.1108360108 PMID: 22143789
34. Huang AS, Baltimore D. Defective viral particles and viral disease processes. Nature. 1970; 226 (5243):325-7. PMID: 5439728
35. Barrett AD, Dimmock NJ. Defective interfering viruses and infections of animals. Current topics in microbiology and immunology. 1986; 128:55-84. PMID: 3533448
36. Roux L, Simon AE, Holland JJ Effects of defective interfering viruses on virus replication and pathogenesis in vitro and in vivo. Advances in virus research. 1991; 40:181-211. PMID: 1957718
37. Santak M, Markusic M, Balija ML, Kopac S.K., Jug R., Orvell C, et al. Accumulation of defective interfering viral particles in only a few passages in Vero cells attenuates mumps virus neurovirulence. Microbes and infection/Institut Pasteur. 2014.
38. Dimmock NJ, Beck S, McLain L. Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. The Journal of general virology. 1986; 67(Pt 5):839-50. PMID: 2422317
39. McLain L, Morgan DJ, Dimmock NJ. Protection of mice from lethal influenza by defective interfering virus: T cell responses. The Journal of general virology. 1992; 73(Pt 2):375-81. PMID: 1371542
40. Qiu X, Fernando L, Melito P.L., Audet J., Feldmann H, Kobinger G, et al Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS neglected tropical diseases. 2012; 6(3): e1575. doi: 10.1371/journal.pntd.0001575 PMID: 22448295
41. Wilson JA, Hevey M, Bakken R., Guest S, Bray M, Schmaljohn A.L., et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000; 287(5458):1664-6. PMID: 10698744
42. van Drunen Littel-van den Hurk S, Luxembourg A, Ellefsen B, Wilson D, Ubach A, Hannaman D, et al. Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle. Vaccine. 2008; 26(43):5503-9. doi: 10.1016/j.vaccine.2008.07.093 PMID: 18708108
43. Kuroiwa Y, Kasinathan P, Sathiyaseelan T., Jiao JA, Matsushita H, Sathiyaseelan J, et al Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nature biotechnology. 2009; 27(2):173-81. doi: 10.1038/nbt.1521 PMID: 19151699
44. Herbert AS, Kuehne AI, Barth J.F., Ortiz RA, Nichols DK, Zak SE, et al Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. Journal of virology. 2013; 87(9):4952-64. doi: 10.1128/JVI.03361-12 PMID: 23408633